Hematology

Tami John, MD, a clinical associate professor at Stanford Medicine, also provided background about the current state of care in TDT.

The 3 FDA-approved CAR T-cell therapies showed comparable survival outcomes in DLBCL over a 3-year period.

Review top news and interview highlights from the week ending June 27, 2025.

The clinical associate professor at Stanford Medicine emphasized the need to build community among patients with TDT.

The clinical associate professor at Stanford Medicine discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinical associate professor at Stanford Medicine also provided background about the current state of care in TDT.

Review top news and interview highlights from the week ending June 20, 2025.

In honor of World Sickle Cell Day, observed annually on June 19, we took a look back at news and expert insights from the past year in cell and gene therapy for SCD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The hematologist at the Hematology and Stem Cell Transplants Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome discussed a study on the effect of comorbidities in patients receiving CAR-T.

Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial.

The head of the clinical development program at Galapagos discussed the company's data presented at EHA's 2025 Congress.

The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.

Review top news and interview highlights from the week ending June 13, 2025.

The associate professor of medicine at Stanford University School of Medicine discussed safety and efficacy data from a study presented at EHA's 2025 congress.

The overall response rate for the 11 treated patients was 72.7% at 3 months posttreatment.

The study included 3 boys and 6 girls who were treated with gene therapy for TDT at 5 to 16 years of age.

The data, from a study of 15 patients, were presented at EHA’s 2025 Congress.

The internal medicine resident at SUNY Upstate Medical University Hospital discussed the implications of findings from a deidentified database of EMR data.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The principal scientist at Bristol Myers Squibb discussed a biomarker analysis she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed next steps after early promising results were presented at ASCO’s 2025 meeting.